221 related articles for article (PubMed ID: 24762809)
41. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
42. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
43. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
44. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
[TBL] [Abstract][Full Text] [Related]
45. Differential methylation of G-protein coupled receptor signaling genes in gastrointestinal neuroendocrine tumors.
Byun S; Affolter KE; Snow AK; Curtin K; Cannon AR; Cannon-Albright LA; Thota R; Neklason DW
Sci Rep; 2021 Jun; 11(1):12303. PubMed ID: 34112938
[TBL] [Abstract][Full Text] [Related]
46. [Study of RASSF1A expression and promoter demethylation in Hep-2 cell line].
Yang J; Ji W; Qu Y; He L; Zhao X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Jan; 25(2):64-6. PubMed ID: 21473137
[TBL] [Abstract][Full Text] [Related]
47. Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors.
Walter D; Harter PN; Battke F; Winkelmann R; Schneider M; Holzer K; Koch C; Bojunga J; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Waidmann O
Sci Rep; 2018 Feb; 8(1):3811. PubMed ID: 29491456
[TBL] [Abstract][Full Text] [Related]
48. Loss of Chromosome 18 in Neuroendocrine Tumors of the Small Intestine: The Enigma Remains.
Nieser M; Henopp T; Brix J; Stoß L; Sitek B; Naboulsi W; Anlauf M; Schlitter AM; Klöppel G; Gress T; Moll R; Bartsch DK; Heverhagen AE; Knoefel WT; Kaemmerer D; Haybaeck J; Fend F; Sperveslage J; Sipos B
Neuroendocrinology; 2017; 104(3):302-312. PubMed ID: 27222126
[TBL] [Abstract][Full Text] [Related]
49. LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype.
Anwar SL; Hasemeier B; Schipper E; Vogel A; Kreipe H; Lehmann U
PLoS One; 2019; 14(5):e0216374. PubMed ID: 31059558
[TBL] [Abstract][Full Text] [Related]
50. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
51. The effect of EBV on WIF1, NLK, and APC gene methylation and expression in gastric carcinoma and nasopharyngeal cancer.
Zhao Z; Liu W; Liu J; Wang J; Luo B
J Med Virol; 2017 Oct; 89(10):1844-1851. PubMed ID: 28543390
[TBL] [Abstract][Full Text] [Related]
52. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
53. Aberrant promoter methylation of SPARC in ovarian cancer.
Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
[TBL] [Abstract][Full Text] [Related]
54. Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells.
Cui X; Wakai T; Shirai Y; Yokoyama N; Hatakeyama K; Hirano S
Hum Pathol; 2006 Mar; 37(3):298-311. PubMed ID: 16613325
[TBL] [Abstract][Full Text] [Related]
55. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.
Geli J; Kiss N; Karimi M; Lee JJ; Bäckdahl M; Ekström TJ; Larsson C
Clin Cancer Res; 2008 May; 14(9):2551-9. PubMed ID: 18451216
[TBL] [Abstract][Full Text] [Related]
56. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
57. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines.
Patel AC; Anna CH; Foley JF; Stockton PS; Tyson FL; Barrett JC; Devereux TR
Carcinogenesis; 2000 Sep; 21(9):1691-700. PubMed ID: 10964101
[TBL] [Abstract][Full Text] [Related]
58. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.
Hesson L; Bièche I; Krex D; Criniere E; Hoang-Xuan K; Maher ER; Latif F
Oncogene; 2004 Mar; 23(13):2408-19. PubMed ID: 14743209
[TBL] [Abstract][Full Text] [Related]
59. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
60. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.
Wang J; Walsh G; Liu DD; Lee JJ; Mao L
Cancer Res; 2006 Sep; 66(17):8361-6. PubMed ID: 16951144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
